Concise Prescribing Info
Acne vulgaris.
Dosage/Direction for Use
Adult : Topical As 0.1% soln/cream/gel or 0.3% gel: Apply once daily at night.
Dosage Details
Acne vulgaris
Adult: As 0.1% soln/cream/gel or 0.3% gel: Apply thinly onto affected areas once daily at night after cleansing.
Special Precautions
Not intended for application to broken, sunburnt or eczematous skin. Pregnancy and lactation.
Adverse Reactions
Mild skin irritation, scaling, erythema, dryness, stinging and burning, pruritus, rash, eczema, acne flare, dermatitis, skin discolouration, sunburn.
Patient Counseling Information
Avoid exposure to excessive sunlight and UV irradiation.
Drug Interactions
Additive irritant effects w/ peeling agents, astringents, abrasive cleaners, strong drying agents or irritant products (e.g. aromatic and alcoholic agents).
Description: Adapalene normalises the differentiation of follicular epithelial cells resulting in decreased microcomedone formation. It binds to specific retinoic acid nuclear receptors.
Onset: 8-12 wk.
Absorption: Minimal.
Excretion: Via bile. Terminal elimination half-life: 7-51 hr (gel).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Adapalene, CID=60164, (accessed on Jan. 20, 2020)

Store between 20-25°C. Protect from light.
ATC Classification
D10AD03 - adapalene ; Belongs to the class of topical retinoid preparations used in the treatment of acne.
Adapalene Cream (E. Fougera & Co.). DailyMed. Source: U.S. National Library of Medicine. Accessed 17/05/2016.

Anon. Adapalene. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 17/05/2016.

Buckingham R (ed). Adapalene. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 17/05/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Adapalene (Topical). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 17/05/2016.

Disclaimer: This information is independently developed by MIMS based on Adapalene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
  • Deriva MS
  • Deriva/Deriva-C
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in